Cannabis extrAct in oncology Patients for the treatment of TUmor Related symptom burden (CAPTURE)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519568-42-00

Acronym

CAPTURE

Enrollment

156

Registered

2025-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

Brief summary

ESAS-TSDS, defined as the total score derived from the sum of individual ratings for each of the nine symptoms included in the ESAS questionnaire.

Detailed description

1. NRS-2002 (Nutrition Risk Screening) score 2. Global Pittsburgh Sleep Quality Index (PSQI) score, reported as both the proportion of patients with sleep disturbances and the median total score 3. Douleur Neuropathique 4 (DN4) questionnaire score, reported as the proportion of patients with neuropathic pain and the median total score 4. Brief Fatigue Inventory (BFI) score 5. ESAS subscores at 8 weeks 6.Proportion of responders based on ESAS-TSDS at 8 weeks 7.Proportion of patients requiring

Interventions

DRUGDescription and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy.

DRUGCannabis Extract Avextra 10/10 Solution

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
ESAS-TSDS, defined as the total score derived from the sum of individual ratings for each of the nine symptoms included in the ESAS questionnaire.	—

Secondary

Measure	Time frame
1. NRS-2002 (Nutrition Risk Screening) score 2. Global Pittsburgh Sleep Quality Index (PSQI) score, reported as both the proportion of patients with sleep disturbances and the median total score 3. Douleur Neuropathique 4 (DN4) questionnaire score, reported as the proportion of patients with neuropathic pain and the median total score 4. Brief Fatigue Inventory (BFI) score 5. ESAS subscores at 8 weeks 6.Proportion of responders based on ESAS-TSDS at 8 weeks 7.Proportion of patients requiring	—

Measure

Time frame

—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026